Introduction
============

Although *BRCA1* and *BRCA2* mutations are well-known predispositions for breast cancer \[[@B1][@B2]\], they account for less than 20% of all familial breast cancer cases \[[@B3]\]. In addition to these high-penetrance breast cancer predisposition genes, moderate-penetrance breast cancer susceptibility genes, such as *ATM*, *BRIP1*, *CHEK2*, and *PALB2*, are associated with 2- to 4-fold relative risk of breast cancer \[[@B3]\]. Genome-wide association studies have identified common low-penetrance breast cancer susceptibility alleles \[[@B4]\]. However, only 35% of the familial risk of breast cancer is explained by these high-to-low-penetrance susceptibility alleles, and a large proportion of the genetic contribution to breast cancer remains unexplained \[[@B3][@B5]\].

Exome sequencing is a technique used to sequence protein-coding regions, which constitute only 1% of the human genome, but account for 85% of known disease-related mutations. This technique can be applied to various human diseases including Mendelian diseases, and could be a promising strategy for identifying new genes associated with an increased risk of breast cancer \[[@B5][@B6][@B7]\], especially in BRCA-negative familial breast cancer.

In addition to younger age at onset of breast cancer \[[@B8]\], there are several distinctive features of breast cancer in Korea \[[@B9][@B10][@B11]\]. Unlike the Ashkenazi-Jewish population, highly recurrent founder mutations have not been detected, while the *BRCA2* c.7480c\>T mutation has been suggested as a candidate founder mutation in Korea \[[@B9]\]. Some moderate-penetrance breast cancer susceptibility alleles, such as *PALB2* 1592delT and 229delT and *CHEK2* 1100delC, are not present in Korean patients \[[@B10][@B11]\]. Although the Korean Hereditary Breast Cancer (KOHBRA) study estimated the nationwide prevalence of *BRCA* mutations among a high-risk group of patients with hereditary breast cancer \[[@B12]\], there has been no study using exome sequencing in familial breast cancer. As a preliminary study, we performed exome sequencing in a breast cancer family without *BRCA* mutations.

Materials and Methods
=====================

1. Patients
-----------

A Korean family that three sisters have a history of breast cancer was selected for analysis ([Fig. 1](#F1){ref-type="fig"}). The second sister had simultaneous breast and thyroid cancer, and another sister without breast cancer had a history of thyroid cancer. There were no members with breast or thyroid cancer in the previous generation. The second sister underwent genetic testing for *BRCA* and *BRAF* mutations and *BRAF*^V600E^ mutation, a somatic mutation \[[@B13]\], was detected. However, no mutation was detected in the *BRCA1* and *BRCA2* genes, even by the multiplex ligation-dependent probe amplification method.

We applied the linkage strategy introduced previously \[[@B7]\]. The second and fourth sisters with breast cancer were sequenced as affected members, while the mother of the sisters was sequenced as a non-affected member.

2. Whole exome sequencing
-------------------------

After informed consent was acquired, whole exome sequencing was performed through an exome sequencing service from Macrogen (South Korea), and the human exome capture by the Agilent V4+UTRs exome enrichment kit was used. Next-generation sequencing followed, using the Illumina HiSeq 2000 sequencer for captured DNA as paired end reads (100 bp). Data analysis was conducted by the Macrogen exome sequencing pipeline.

All samples were sequenced to provide mean sequence coverage of more than 150×, with more than 95% of the target bases having at least 10× coverage. Approximately 99.7% of all initial mappable reads were able to pass our thresholds for SNPs and short insertions or deletions (indels). The mean read depth of the target regions was 82.4×, 84×, and 91.4×, respectively. The throughput of the exome sequence is summarized in [Table 1](#T1){ref-type="table"}.

3. Variant calling and analysis
-------------------------------

Sequence variants including single-nucleotide variations (SNVs) and small insertional-deletional variations (indels) were called using SAMtools (ver. 0.1.18). The SNVs and indels were annotated by the ANNOVAR program (ver. November 2011) \[[@B14]\], where the files were converted to their input format, variations within exonic or splicing regions were selected, and synonymous SNVs were filtered out. Then, and in-house program was applied to filter out the indels and additional SNVs that have been reported in common variant databases including dbSNP135 or 1000 Genomes SNP call release (20101109, 628 individuals) \[[@B15]\]. Lastly, all selected variants were annotated using dbNSFP \[[@B16]\], which is a database developed for functional prediction and annotation of all potential non-synonymous single-nucleotide variants (nsSNVs) in the human genome.

We used Sorting Intolerant From Tolerant (SIFT), PolyPhen-2, and MutationTaster to assess the impact of mutations on protein function. SIFT examines the degree of conservation for amino acid residues across species, and PolyPhen-2 finds change in protein structure and function. MutationTaster checks both, and additionally looks at effects on splicing or mRNA expression.

Results
=======

We identified 19,436, 19,468, and 19,345 SNPs in the coding regions, respectively (8,759, 8,789, and 8,772 non-synonymous SNPs). After identification of variants, we merged variations from the three samples, and then extracted 124,440 total variations. We focused only on the relevant variation for each phenotype, including exonic variants, which are variants that overlap a coding exon, and splicing variants, which are variants within 2 bp of a splicing junction. A total of 25,435 variants remained after selection process. We then filtered out an additional 12,843 synonymous variations, and 12,105 known variations, which are represented in the dbSNP135, 1000 Genomes Project with indels. Finally, we selected 73 variations that did not exist in the sample from the unaffected mother, but were in the samples from the affected sisters by assuming a dominant genetic model, and we identified 64 genes that contained these variations.

The missense prediction programs, SIFT, PolyPhen-2, and MutationTaster were used and the different scores from these tools were derived for the final 73 candidate variants. SIFT predicts whether an amino acid substitution in a protein will have a phenotypic effect, and the score less than 0.05 are predicted to be deleterious, those greater than or equal to 0.05 are predicted to be tolerated. PolyPhen-2 predicts the functional significance of an allele replacement, and the score more than 0.85 are interpreted as probably damaging and scores 0.15-0.85 as possibly damaging. MutationTaster predicts the disease potential of an alteration, and the predicted value close to 1 indicates a high \'security\' of the prediction. Results from the three different tools were compared, and we identified that 7 variants were reported risky among all three algorithms: *XCR1*, *DLL1*, *TH*, *ACCS*, *SPPL3*, *CCNF*, and *SRL* ([Fig. 2](#F2){ref-type="fig"}, [Table 2](#T2){ref-type="table"}). The variants were confirmed by Sanger sequencing.

Discussion and Conclusion
=========================

In the current study, we found 7 variants that could affect protein function through exome sequencing followed by subsequent filtering and selection by SIFT, Polyphen-2, and MutationTaster. We searched literatures regarding potential relationship between the variants and breast cancer. Among the 7 variants, 3 variants were related to breast cancer. The *XCR1*, a chemokine receptor belonging to the G protein-coupled receptor superfamily, has been known to be involved in cytotoxic immune response \[[@B17][@B18]\]. With regard to breast cancer, Gantsev et al. \[[@B19]\] demonstrated the increase in expression of the genes *CCL16*, *XCR1*, *CYFIP2*, and *TNFSF14* in newly formed lymph nodes in breast cancer. The *DLL1* gene encodes for delta-like protein 1, which acts as a ligand for Notch receptors that engage in oncogenic conversion of human breast epithelial cells \[[@B20]\]. Furthermore, inhibition of Notch signaling is suggested to be beneficial for breast cancer \[[@B21]\]. The *CCNF*, a member of the cyclin family, is known to be involved in mitosis and genome integrity during the G2 phase of the cell cycle in association with CP110 \[[@B22]\]. Roy et al. \[[@B23]\] demonstrated that etodolac, a member of the cyclooxygenase inhibitor, altered 6 cell cycle regulatory protein genes of mammary epithelial cells, including *CCNF*.

Several genes are related to breast cancer as described above, and could be potential candidates for breast cancer predisposition. However, definite candidate genes could not be conclusively determined because only one family with two affected members was examined. However, this preliminary study could help explain non-*BRCA* familial breast cancer. Lynch et al. \[[@B24]\] suggested that genetic predisposition for familial breast cancer could be family-specific, which would be difficult to detect using a population-based approach. Therefore, exome sequencing data from a single family could be valuable for determining genetic predisposition.

Future studies should seek to identify candidate families who could benefit from exome sequencing. According to the KOHBRA study, the prevalence of *BRCA* mutations among familial breast cancer probands was 21.7% \[[@B12]\]. The remaining 78.3% of the familial breast cancer probands who were negative for *BRCA* mutations could be potential candidates for exome sequencing. In addition to a family history of breast cancer, Han et al. \[[@B12]\] suggested that age at diagnosis (\<50 years) should also be considered when selecting patients for genetic testing. In this regard, genetic anticipation, a phenomenon of early onset of disease in subsequent generations, should also be considered, because the generational difference in age at diagnosis could be attributed to genetic predisposition, with or without *BRCA* mutation \[[@B25]\]. Exome sequencing could explain the actions of moderate to low penetrance susceptibility alleles of non-*BRCA* breast cancer families, which are considered high risk for breast cancer and include several affected women across generations \[[@B6]\].

Several limitations should be considered in regard to the current study. First, only one affected breast cancer patient, the second sister, underwent genetic testing for *BRCA* mutations. Second, distant affected young relative and nearby unaffected old relative should be added to the analysis to validate susceptible variants. But the selection of the family was not satisfactory for such analysis. Third, we chose the unaffected mother rather than the breast cancer-free sister. Since the sister relations are likely to be genetically identical, the unaffected sister should be considered to be chosen.

In summary, we found 7 variants by exome sequencing for breast cancer family without *BRCA* mutations. The *XCR1*, *DLL1*, *TH*, *ACCS*, *SPPL3*, *CCNF*, and *SRL* genes could be potential candidates for breast cancer predisposition. Genetic evidence of disease association should be confirmed by validation through additional non-*BRCA* breast cancer families and comparison with general population.
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###### The throughput of the exome sequence in this study
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SNP, single-nucleotide polymorphism; indel, insertional-deletional variations.

###### Candidate variants shared by affected individuals and selected by SIFT, PolyPhen-2, and MutationTaster algorithms
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SIFT, Sorting Intolerant From Tolerant.

^a)^Genomic position from HG build 19.
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